

WHO Immunological Basis for Immunization Series

**Module 4: Pertussis
Update 2017**

Immunization, Vaccines and Biologicals



**World Health
Organization**

The immunological basis for immunization series: module 4: pertussis (Immunological basis for immunization series ; module 4)

ISBN 978-92-4-151317-3

© World Health Organization 2017

Some rights reserved. This work is available under the
Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence
(CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. The immunological basis for immunization series: module 4: pertussis.
Geneva: World Health Organization; 2017 (Immunological basis for immunization series; module 4).
Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>.
To submit requests for commercial use and queries on rights and licensing,
see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

WHO Immunological Basis for Immunization Series

**Module 4: Pertussis
Update 2017**

Immunization, Vaccines and Biologicals



**World Health
Organization**

Contents

Abbreviations and acronyms.....	v
Preface.....	vii
1. Pertussis	1
2. Antigens of <i>Bordetella pertussis</i>	3
2.1 Regulation of antigen production	3
2.2 Pertussis toxin	3
2.3 Adenylate cyclase toxin.....	4
2.4 Lipopolysaccharide	4
2.5 Dermonecrotic toxin, heat-labile toxin	4
2.6 Tracheal cytotoxin	5
2.7 Filamentous haemagglutinin	5
2.8 Pertactin	5
2.9 Fimbriae.....	6
2.10 Animal models of <i>Bordetella pertussis</i> infection	6
3. Pertussis vaccines.....	7
3.1 Whole-cell pertussis vaccines	7
3.2 Acellular pertussis vaccines.....	8
3.3 Combination vaccines	10
3.4 Combination vaccines with whole-cell pertussis components	11
3.5 Combination vaccines with acellular pertussis vaccine.....	12
4. Measuring the immune response to <i>Bordetella pertussis</i> antigens	13
4.1 Bacterial agglutination test	14
4.2 Enzyme-linked immunosorbent assay	14
4.3 Immunoblot assays.....	15
4.4 Other tests for measuring antibodies	15
4.5 Tests for cell-mediated immunity.....	16
5. Immune responses after exposure to <i>Bordetella pertussis</i>	17
5.1 Development of antibodies after primary infection	17
5.2 Immune responses after non-primary stimulation	17
5.3 Transplacental passage of antibodies.....	19
5.4 Antibody decay after natural infection.....	20
5.5 Duration of protection after natural infection	20

6. Immune responses to vaccination	21
6.1 Type of immunity induced by whole-cell and acellular vaccines.....	21
6.2 Response to whole-cell pertussis vaccine	25
6.3 Antibody decay after immunization with whole-cell vaccines	26
6.4 Effectiveness of whole-cell pertussis vaccine in infants and toddlers.....	26
6.5 Effectiveness of incomplete primary series of whole-cell pertussis vaccine.....	26
6.6 Effectiveness of whole-cell vaccine in adolescents and adults.....	27
6.7 Immune responses to acellular pertussis vaccines	27
6.8 Antibody decay after immunization with acellular vaccines	28
6.9 Effectiveness of acellular vaccines in infants and toddlers.....	29
6.10 Effectiveness of incomplete primary series of acellular vaccines	29
6.11 Effectiveness of acellular vaccines in adolescents and adults.....	30
6.12 Effectiveness of maternal immunization to prevent infant pertussis	30
6.13 Correlates of protection for pertussis vaccines	30
6.14 Interchangeability of pertussis vaccines	31
6.15 Sero-surveys for <i>Bordetella pertussis</i> antibodies	32
6.16 Duration of protection after vaccination with whole-cell vaccines	33
6.17 Duration of protection after vaccination with acellular vaccines	34
7. Conclusions and perspectives	35
8. Summary.....	36
9. References	37
Acknowledgements.....	59
Conflict of interest.....	60

Abbreviations and acronyms

AC	adenylate cyclase
ACT	adenylate cyclase toxin
AGG	agglutinogens
aP	acellular pertussis (vaccine)
BA	bacterial agglutination
BrkA	Bordetella resistance to killing genetic locus, frame A
BvgAS	complex virulence expression system
CHO	Chinese hamster ovary (cells)
CMI	cell-mediated immunity
DNT	dermonecrotic toxin
DTaP	diphtheria–tetanus–acellular pertussis
DTP	diphtheria-tetanus-pertussis vaccine
DTwP	diphtheria–tetanus whole-cell pertussis (vaccine)
ELISA	enzyme-linked immunosorbent assay
ELISPOT	enzyme-linked immunospot assay
EPI	Expanded Programme on Immunization
ESEN	European Sero-Epidemiology Network
FHA	filamentous haemagglutinin
FIM	fimbriae
GMT	geometric mean titre
GSK	GlaxoSmithKline
HCW	health-care worker
Hib	Haemophilus influenzae type b
HLT	heat-labile toxin
ICS	intracellular cytokine secretion
Ig	immunoglobulin
IPV	inactivated polio vaccine
Lf	flocculation units of toxoid

LOS	lipooligosaccharide
LPS	lipopolysaccharide
MRC	Medical Research Council
NACI	National Advisory Committee on Immunization
NIBSC	National Institute for Biological Standards & Control
NIH	National Institutes of Health
NT	neutralization test
OMP	outer membrane protein
PRN	pertactin
PRP	polyribosyl-ribitol-phosphate
PT	pertussis toxin
RGD	arginine-glycine-aspartic acid
RTX	repeats-in-toxin
SphB1	serine-protease/lipoprotein
TCT	tracheal cytotoxin
Tdap	DTaP with reduced antigen content
VE	vaccine efficacy
WHO	World Health Organization
wP	whole-cell pertussis (vaccine)

Preface

This module is part of the WHO series The Immunological Basis for Immunization, which was initially developed in 1993 as a set of eight modules, comprising one module on general immunology and seven modules each devoted to one of the vaccines recommended for the Expanded Programme on Immunization, i.e. vaccines against diphtheria, measles, pertussis, polio, tetanus, tuberculosis and yellow fever. Since then, this series has been updated and extended to include other vaccines of international importance.

The main purpose of the modules is to provide national immunization managers and vaccination professionals with an overview of the scientific basis of vaccination against a range of important infectious diseases. The modules developed since 1993 continue to be vaccine-specific, reflecting the biological differences in immune responses to the individual pathogens and the differing strategies employed to create the best possible level of protection that can be provided by vaccination. The modules also serve as a record of the immunological basis for the WHO recommendations on vaccine use, published in the WHO vaccine position papers.*

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_26615

